Samsung Biologics Secures Top ESG Rating From Morningstar Sustainalytics

Incheon, South Korea, November 4, 2026 - Samsung Biologics, a prominent contract development and manufacturing organization (CDMO), has attained a Negligible Risk rating in the latest Morningstar Sustainalytics ESG Risk Ratings assessment. This marks a significant improvement in the company's environmental, social, and governance (ESG) performance.

The ESG Risk Rating score is now 9.0, up from its previous Low Risk rating, placing Samsung Biologics among the top 0.5% of companies evaluated in the pharmaceutical sector. Morningstar Sustainalytics, an independent ESG research and ratings provider, evaluates around 16,000 companies worldwide based on their exposure to material ESG risks and the effectiveness of managing those risks.

Scores below 10 indicate a negligible level of unmanaged ESG risk, with lower scores denoting lower overall risk. The enhanced rating is a result of Samsung Biologics' ongoing efforts to bolster ESG management across its operations. The company has introduced measures to improve environmental auditing, occupational health and safety, quality management, and business ethics, while strengthening internal processes and oversight to detect and mitigate potential risks.

John Rim, President and CEO of Samsung Biologics, stated, "Effective risk management is crucial to our global CDMO operations. This recognition validates the progress we've made in integrating responsible practices throughout our business." With the expansion of its global footprint, Samsung Biologics remains committed to a disciplined approach in risk management and maintaining the confidence of its clients and stakeholders.

The company's latest achievement follows its recent A rating in the 2026 MSCI ESG Ratings assessment and its EcoVadis Platinum Sustainability Rating, which ranks it among the top 1% of companies globally assessed.